Abstract 126

Abstract

Background: Octreotide long-acting release (LAR) is a medication used for acromegaly thatcan normalize insulin-like growth factor-1 (IGF-1) and serum growth hormone (GH) levels, leadto tumor shrinkage, and improvement of symptoms of disease activity. Previous studies arelacking regarding the long-term efficacy in Indian populations. This retrospective study aimed toevaluate its effectiveness in a cohort of Indian patients with acromegaly. Methods: Overall, 26 patients with acromegaly, who received regular octreotide LARtreatment at least 6 times at SSKM & IPGMER Hospital between 2017 and 2022, were included. Epidemiological characteristics, acromegaly activity, IGF-1 levels, MRI data pre and posttreatment were collected for investigation. Results: The study registered 26 patients, including 10 men (38%) with a mean age 33 years. After octreotide LAR therapy, 82% of the patients achieved IGF-1 control (<250 ng/dL). 15 patients had reduction in features of disease activity; at baseline 83% patients had clinicallyactive disease. MRI data at both baseline & current (minimum of 6 months following initiationof therapy) was available in 14 patients; 6 had reduction in tumor size by 50% & 8 had reduction < 50% on MRI compared to baseline. During the follow-up, 1 of the patients discontinuedoctreotide LAR. Conclusions: Our study revealed that octreotide LAR therapy is effective in normalizing IGF1 levels in Indian acromegaly patients. It is also effective agent in alleviating symptoms andinducing tumor shrinkage. It should be recommended for post-surgical residual disease, and alsobe considered as primary therapy for selected cases, mainly for those with a low probability ofsurgical cure or those with contra-indications for surgery.